CurrentCignaPolicy N/A

Oncology - Jakafi Prior Authorization Policy

Cigna prior authorization policy for Jakafi (ruxolitinib tablets) specifying indications covered, clinical criteria for approval, duration of approvals, supportive evidence uses, and investigational exclusions for other uses.

Policy Summary

PayerCigna

PolicyOncology - Jakafi Prior Authorization Policy

Policy CodePolicy N/A

Change TypeClarified / Revised / Added

Effective Date

Next Review DateFeb 19, 2025

Key ActionPrior authorization is recommended/required for prescription benefit coverage of Jakafi; approvals provided for 1 year when criteria are met.

SourceLink

POLICY UPDATE CHANGES

Polycythemia Vera criteria expanded to include Pegasys (peginterferon alfa-2a) as an agent the patient must have tried.

T-Cell Lymphoma criteria were added/updated to specify peripheral T-cell lymphoma qualifier and other subtype qualifiers, and requirement for prior systemic regimen was modified to apply to specific subtypes.

Accelerated or Blast Phase Myeloproliferative Neoplasm approval criteria were added to Other Uses with Supportive Evidence.

11Listed Indications (FDA + supportive evidence)

1Approval duration (years)

≥12/≥18/<21Age thresholds (examples)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

Coverage: covered_with_criteria for FDA-approved and selected supportive-evidence indications. Scope: Cigna prior authorization policy specifying covered indications, clinical criteria, and investigational exclusions. Approval duration: 1 year for all approvals. Alignment: policy aligns coverage to FDA indications and selected NCCN-recommended/supportive evidence uses, with prior therapy and mutation-dependent criteria applied for some non‑FDA uses.

FDA-Approved Indications

Jakafi is covered as medically necessary for the following FDA-approved indications when ALL criteria listed for each indication are met. Approvals are for 1 year unless noted.

Indication: Graft-Versus-Host Disease, Acute

ALL of the following
- Patient is ≥ 12 years of age
- Patient has tried one systemic corticosteroid

Indication: Graft-Versus-Host Disease, Chronic

ALL of the following
- Patient is ≥ 12 years of age
- Patient has tried one conventional systemic treatment for graft-versus-host disease
  See examples in policy definitions

Indication: Myelofibrosis

Patient is ≥ 18 years of age

Indication: Polycythemia Vera

Patient is ≥ 18 years of age
Patient has tried hydroxyurea, Pegasys (peginterferon alfa-2a), or Besremi (ropeginterferon alfa-2b)

Other Uses with Supportive Evidence

Jakafi may be approved for the following non-FDA labeled uses when ALL/other criteria below are met. Approvals are for 1 year.

Indication: Accelerated or Blast Phase Myeloproliferative Neoplasm

Patient is ≥ 18 years of age
Patient has at least one disease-related symptom
Examples include fatigue, fever, night sweats, weight loss, abdominal discomfort, splenomegaly, thrombocytosis, or leukocytosis.

Indication: Acute Lymphoblastic Leukemia (ALL)

Patient is < 21 years of age
The mutation/pathway is Janus Associated Kinase (JAK)-related

Atypical Chronic Myeloid Leukemia (includes MDS/MPN with neutrophilia)

Not Covered / Experimental/Investigational

Jakafi is considered experimental, investigational, or unproven for any other uses not listed above.

Any other indication or use not specified in the FDA-approved or supportive evidence sections

Provider Actions

Prior Authorization

Prior authorization required

Prior authorization is recommended/required for prescription benefit coverage of Jakafi. Approvals are provided for 1 year when criteria are met.

Documentation Required

Document prior therapies / mutations

Provider must document age, prior therapies tried, and relevant mutation/pathway status as applicable for the requested indication.

Age (examples: ≥12 years for acute/chronic GVHD; ≥18 years for most adult indications; <21 years for ALL supportive-use)
Prior therapies tried (examples: systemic corticosteroid for acute GVHD; conventional systemic therapy for chronic GVHD; hydroxyurea, Pegasys, or Besremi for polycythemia vera; hypomethylating agent for CMML‑2)
Mutation/pathway status (examples: JAK-related pathway, JAK2 mutation, CSF3R mutation)

Applicable Codes

DrugNDCCovered

No codes listed

Clinical Evidence & Guidelines

Key references include the Jakafi prescribing information (Incyte, Jan 2023) and multiple NCCN guideline versions (2024–2025). The policy aligns to FDA indications and selected NCCN/supportive evidence recommendations for additional uses (e.g., CMML-2, atypical CML with CSF3R or JAK2 mutations, myeloproliferative neoplasms, T‑cell lymphomas, pediatric ALL). Background examples note the JAK inhibitor class and related clinical contexts where Jakafi is used.

Background

Jakafi (ruxolitinib) is a JAK1/JAK2 inhibitor indicated for steroid‑refractory acute GVHD (patients ≥12), chronic GVHD after failure of systemic therapy (patients ≥12), myelofibrosis in adults, and polycythemia vera in adults intolerant of or with inadequate response to hydroxyurea. The policy aligns coverage to FDA indications and to selected NCCN-recommended/supportive evidence uses; some non‑FDA uses require prior therapies and/or presence of specific mutations or JAK-related pathway activation (e.g., CSF3R or JAK2 mutations, JAK-related ALL).

Definitions: Conventional systemic treatment for chronic GVHD includes examples such as systemic corticosteroids (methylprednisolone, prednisone), cyclosporine, tacrolimus, mycophenolate mofetil, ibrutinib, belumosudil, axatilimab‑csfr, pentostatin, rituximab, abatacept, hydroxychloroquine, and imatinib. Hypomethylating agents include examples such as azacitidine and decitabine.

Revision History

03/22/2023clarified

Polycythemia Vera criteria expanded to include Pegasys (peginterferon alfa-2a) as an agent the patient must have tried.

03/20/2024revised

02/19/2025addedLatest